Published in Dig Dis Sci on November 05, 2009
MiR-278-3p regulates pyrethroid resistance in Culex pipiens pallens. Parasitol Res (2014) 0.84
Hepatic Stellate Cells and microRNAs in Pathogenesis of Liver Fibrosis. J Clin Med (2016) 0.84
Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice. Lab Invest (2016) 0.76
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Prediction of mammalian microRNA targets. Cell (2003) 53.70
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
MicroRNA genes are transcribed by RNA polymerase II. EMBO J (2004) 20.65
Prediction of plant microRNA targets. Cell (2002) 19.20
Liver fibrosis. J Clin Invest (2005) 17.27
MicroRNAS and their regulatory roles in plants. Annu Rev Plant Biol (2006) 14.44
microRNA target predictions in animals. Nat Genet (2006) 10.76
Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell (2002) 10.30
Sequence requirements for micro RNA processing and function in human cells. RNA (2003) 7.46
Facile means for quantifying microRNA expression by real-time PCR. Biotechniques (2005) 5.04
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest (2007) 4.41
Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med (2006) 3.84
A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA (2006) 3.71
MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol (2007) 3.38
An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J Lipid Res (2000) 2.36
Structure of eukaryotic RNA polymerases. Annu Rev Biophys (2008) 2.28
In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A (1999) 2.17
Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med (2007) 2.14
Collagen types in normal and cirrhotic liver. Gastroenterology (1979) 2.09
Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci U S A (1999) 1.95
The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology (2001) 1.88
An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res (2005) 1.83
TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet (2007) 1.77
Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology (2004) 1.73
Gene therapy progress and prospects: synthetic polymer-based systems. Gene Ther (2008) 1.58
MicroRNAs and endocrine biology. J Endocrinol (2005) 1.47
Intronic microRNA (miRNA). J Biomed Biotechnol (2006) 1.40
Discrete clusters of virus-encoded micrornas are associated with complementary strands of the genome and the 7.2-kilobase stable intron in murine cytomegalovirus. J Virol (2007) 1.39
Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today (2008) 1.37
Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice. J Clin Invest (1997) 1.37
RNAi mechanisms and applications. Biotechniques (2008) 1.30
Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med (2006) 1.27
TGF-beta1 gene silencing for treating liver fibrosis. Mol Pharm (2009) 1.13
Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets (2008) 1.11
The antifibrotic effect of TGF-beta1 siRNAs in murine model of liver cirrhosis. Biochem Biophys Res Commun (2006) 1.06
Targeted expression of a protease-resistant IGFBP-4 mutant in smooth muscle of transgenic mice results in IGFBP-4 stabilization and smooth muscle hypotrophy. J Biol Chem (2002) 0.89
Identification and characterization of the hepatic stellate cell transferrin receptor. Am J Pathol (2003) 0.88
Gene therapy for hepatic fibrosis-bringing treatment into the new millennium. Hepatology (1999) 0.85
New therapeutic approaches to liver fibrosis: a practicable route? Curr Med Chem (2008) 0.84
Targeting gene therapy for hepatocarcinoma cells with the E. coli purine nucleoside phosphorylase suicide gene system directed by a chimeric alpha-fetoprotein promoter. Cancer Lett (2008) 0.83
Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice. Hepatobiliary Pancreat Dis Int (2009) 0.81
Transgenic RNAi: Accelerating and expanding reverse genetics in mammals. Transgenic Res (2006) 0.81
RNA interference-based gene silencing in mice: the development of a novel therapeutical strategy. Curr Pharm Des (2005) 0.79
Ribozymes against TGFbeta1 reverse character of activated hepatic stellate cells in vitro and inhibit liver fibrosis in rats. J Gene Med (2005) 0.78
Establishment of a screening system for selection of siRNA target sites directed against hepatitis B virus surface gene. Acta Biochim Biophys Sin (Shanghai) (2005) 0.77
[Modified Shengma Biejia Decoction Combined with CAG Program for Elderly Acute Myeloid Leuke- mia Patients with Yin Deficiency Toxin Stasis Syndrome]. Zhongguo Zhong Xi Yi Jie He Za Zhi (2016) 0.86
[Clinical study of lamivudine and interferon combinate administration to inhibit hepatitis B virus replication]. Zhonghua Gan Zang Bing Za Zhi (2004) 0.83
[The association of HLA-DRB1 allele polymorphism with the genetic susceptibility to liver cirrhosis due to hepatitis B virus]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2003) 0.80
[Inhibition of HSP70-2 expression by RNA interference induces apoptosis of human hepatocellular carcinoma cells]. Zhonghua Gan Zang Bing Za Zhi (2008) 0.80
[Clinical study of oligonucleotide microarray on monitoring the lamivudine-resistance mutations in hepatitis B virus]. Zhonghua Gan Zang Bing Za Zhi (2003) 0.79
[Effect and mechanism of beta-L-D4A (a novel nucleoside analog) against hepatitis B virus]. Zhonghua Gan Zang Bing Za Zhi (2003) 0.79
[Establishment and identification of highly expressing and replicating hepatitis B virus genome transgenic mouse models]. Zhonghua Gan Zang Bing Za Zhi (2003) 0.79
[The simultaneous knock-down of Ku70 and Ku80 by a tandem Ku-shRNA-encoding plasmid expression system]. Zhonghua Gan Zang Bing Za Zhi (2007) 0.78
[HBx gene down-regulates miR-192 expression and inhibits apoptosis of human hepatoma cell line HepG2]. Zhonghua Gan Zang Bing Za Zhi (2011) 0.78
[Establishment and identification of L02 cell line transfected by HBV genome]. Zhonghua Gan Zang Bing Za Zhi (2005) 0.77
[Establishment of a new HBV genotyping method with PCR-RBD and its application]. Zhonghua Gan Zang Bing Za Zhi (2004) 0.77
[Inhibition of the replication of hepatitis B virus in vitro by a novel nucleoside analogue (beta-L-D4A)]. Zhonghua Gan Zang Bing Za Zhi (2003) 0.77
[The effects of sympathetic neurotransmitters and adrenergic receptors on liver fibrosis in murine schistosomiasis]. Zhonghua Gan Zang Bing Za Zhi (2008) 0.77
[Effects of norepinephrine on the proliferation and activation of rat hepatic stellate cells]. Zhonghua Gan Zang Bing Za Zhi (2008) 0.77
Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses. J Huazhong Univ Sci Technolog Med Sci (2015) 0.76
[MiR-122 regulates the expression of PEG10 in hepatoma cell lines]. Zhonghua Gan Zang Bing Za Zhi (2010) 0.76
[Expression and significance of hypoxia inducible factor-1 alpha in hepatocellular carcinoma tissues]. Zhonghua Gan Zang Bing Za Zhi (2006) 0.75
[The association between polymorphism of endothelial nitric oxide synthase gene and cirrhotic portal hypertension]. Zhonghua Yi Xue Za Zhi (2003) 0.75
[Clinical significance of cellular immune function in patients with viral myocarditis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2010) 0.75
[Establishment of a model for predicting the prognosis in patients with liver cirrhosis]. Zhonghua Gan Zang Bing Za Zhi (2008) 0.75
[The deletion of La protein binding site in HBV RNA leads to instability of S gene mRNA]. Zhonghua Gan Zang Bing Za Zhi (2006) 0.75
[Insertion of TC motif into hepatitis B virus core protein c/e1 site does not affect the expression of S and e antigen]. Zhonghua Gan Zang Bing Za Zhi (2009) 0.75
[A case report of portopulmonary hypertension]. Zhonghua Gan Zang Bing Za Zhi (2012) 0.75
[Therapeutic effect of secretive endostatin eukaryotic expressing plasmid on mouse hepatoma]. Zhonghua Gan Zang Bing Za Zhi (2003) 0.75
[The role of X protein in the life cycle of hepatitis B virus]. Zhonghua Gan Zang Bing Za Zhi (2003) 0.75
[Expression of ASMase in alcoholic liver fibrosis in rats]. Zhonghua Gan Zang Bing Za Zhi (2013) 0.75
[Construction of recombinant plasmid human imprinted gene PEG10 and the primary functional identification in transfected cell lines]. Zhonghua Gan Zang Bing Za Zhi (2007) 0.75
[Apoptosis of HepG2 cells induced by shRNA targeting X-linked inhibitor of apoptosis protein gene]. Zhonghua Gan Zang Bing Za Zhi (2008) 0.75
[Establishment of PEG10 transgenic mouse and effects of PEG10 on growth, metastasis of transplanted tumor in mice]. Zhonghua Gan Zang Bing Za Zhi (2009) 0.75
[Construction and expression of EGFP controlled HBV promoters in eukaryotic cells]. Zhonghua Gan Zang Bing Za Zhi (2006) 0.75
[The imprinting status of genetic imprinted gene PEG10 in human hepatocellular carcinomas]. Zhonghua Gan Zang Bing Za Zhi (2010) 0.75
[The influence of botulinum toxin on the masticatory muscles of the temporomandibular joint osteoarthritis in rabbit]. Shanghai Kou Qiang Yi Xue (2005) 0.75
[The expression of cannabinoid receptor 1 in fibrotic liver tissues of mice infested with Schistosoma mansoni]. Zhonghua Gan Zang Bing Za Zhi (2007) 0.75
[Hammerhead ribozyme-mediated cleavage of transforming growth factor beta1 RNA in a cell-free system and in hepatic stellate cells]. Zhonghua Gan Zang Bing Za Zhi (2006) 0.75
[2010 guideline for the management of hepatocellular carcinoma recommended by the American Association for the Study of Liver Diseases]. Zhonghua Gan Zang Bing Za Zhi (2011) 0.75
[Inhibition of mutant p53 in hepatocellular carcinoma cells by hammerhead ribozyme]. Zhonghua Gan Zang Bing Za Zhi (2003) 0.75
[Research on molecular markers for epigenetic changes in myeloid malignancies]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2013) 0.75
[Hammerhead ribozyme against human telomerase catalytic subunit (hTERT) induced apoptosis of liver cancer cells]. Zhonghua Gan Zang Bing Za Zhi (2004) 0.75
[A study of the association of iNOS and eNOS gene polymorphism with portal hypertension in liver cirrhosis]. Zhonghua Gan Zang Bing Za Zhi (2005) 0.75
[Great attention should be paid to study of genetic susceptibility of liver cirrhosis]. Zhonghua Yi Xue Za Zhi (2003) 0.75
[Effects of anandamide on the activation and proliferation of hepatic stellate cells through cannabinoid-2 receptors]. Zhonghua Gan Zang Bing Za Zhi (2008) 0.75
[Polymorphism of NOS2A promoter -969(G>C) is associated with portal hypertension of liver cirrhosis]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2004) 0.75
[Two cases of rare abnormality karyotype of chromosome in one family]. Zhonghua Er Ke Za Zhi (2008) 0.75
[Relationship between death receptor 5 and apoptosis in hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi (2006) 0.75
[The relationship between the plasma homocysteine level and the polymorphism of MTHFR gene C667T in liver cirrhosis]. Zhonghua Gan Zang Bing Za Zhi (2005) 0.75
[Relationship of endothelin-1 (ET-1) TaqI and tumor necrosis factor (TNF) a gene polymorphism with portal hypertension in liver cirrhosis]. Zhonghua Gan Zang Bing Za Zhi (2004) 0.75
[A study on transcription regulation of human alpha 2(I) procollagen gene by FoxH-1]. Zhonghua Gan Zang Bing Za Zhi (2007) 0.75
[The inhibitory effects on hepatitis B virus replication by transient expression of dominant negative mutants of hepatitis B virus X gene]. Zhonghua Gan Zang Bing Za Zhi (2003) 0.75
[The effect of exogenous PEG10 on mitochondrial membrane potential of L02 human liver cells and its possible mechanisms]. Zhonghua Gan Zang Bing Za Zhi (2008) 0.75
[Causes and diagnosis of non-portal hypertension ascites: a study of 216 cases]. Zhonghua Gan Zang Bing Za Zhi (2012) 0.75
[Inhibition of mutant-type p53 by a chimeric U6 maxizyme in hepatocellular carcinoma cell lines]. Zhonghua Gan Zang Bing Za Zhi (2005) 0.75